teclistamab,daratumumab,talquetamab
genmab,janssen
['mmsm', ' emd ']
aa4/ rr for the targeted does of (tt) 96%, 89% had vgpr and better, 9 months pfs was 77%. while rr with those with emd was 86% and median pfs was 10 months. #mmsm #myeloma #medtiwtter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter